Pneumonia

Breathe Change: Lung Health Foundation Launches First of Three Landmark Policy Forums on Thursday, March 7

Retrieved on: 
Monday, March 4, 2024
Chairperson, Clinical Practice, RSV, Education, Building, Spirometry, Hospital, Overalls, Asthma, Pneumonia, Assembly, Hope, LHF, Long-term care, Climate change, Patient, Policy, Health policy, Lung cancer, Health professional, Diagnosis, Wildfire, Mortality, Public, Research, Radon, Health insurance

LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.

Key Points: 
  • LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.
  • The session showcases the best-of-the-best in COPD and lung disease research, diagnosis and treatment modalities, and policy initiatives.
  • Dawn Bowdish, Executive Director, Firestone Institute for Respiratory Health and Dr. Maya de Zoysa, Respirologist, West Nipissing General Hospital.
  • For those navigating the labyrinth of lung disease, LHF offers an expansive array of disease-specific support programs and resources.

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024
Aphelion, Sector, FDA, ISC, EQT, Dysphagia, Pneumonia, Stroke, Entrepreneurship, Risk, Conference, Health Economics, Saliva, Patient, Brain, Patient capital, Economics, Mortality, Research, Pharmaceutical industry

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024
Aphelion, Sector, FDA, ISC, EQT, Dysphagia, Pneumonia, Stroke, Entrepreneurship, Risk, Conference, Health Economics, Saliva, Patient, Brain, Patient capital, Economics, Mortality, Research, Pharmaceutical industry

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.

United Imaging Intelligence Unveiled Next-Generation Radiology Solutions at ECR 2024

Retrieved on: 
Friday, March 1, 2024
MRI, UAI, Stroke, Breast cancer, Collection, CE, UII, AI, Cardiovascular disease, Cardiology, Cancer, 3D, Radiology, Exhibition, Pneumonia, Radiation, Myenteric plexus, SAT, ECR, Virtual reality, Certification, Death, Anatomy, Lung cancer, Diagnosis, WHO, Congress, Neurology, Research, Prostate cancer, Medical imaging

VIENNA, March 1, 2024 /PRNewswire/ -- At the European Congress of Radiology (ECR) 2024 in Vienna, United Imaging Intelligence (UII), a subsidiary of United Imaging Group, proudly presented its latest advances in medical AI technology.

Key Points: 
  • VIENNA, March 1, 2024 /PRNewswire/ -- At the European Congress of Radiology (ECR) 2024 in Vienna, United Imaging Intelligence (UII), a subsidiary of United Imaging Group, proudly presented its latest advances in medical AI technology.
  • Renowned for its AI-driven healthcare applications, UII's presentation at ECR 2024 marked a significant leap toward "Next Generation Radiology," showcasing intelligent healthcare solutions in alignment with the congress's forward-looking theme.
  • Amidst the rapid transformation of the medical technology landscape driven by foundation models, UII adopts these crucial frameworks to enhance 'Next Generation Radiology'.
  • At ECR 2024, UII introduced uAI SAT, an innovative AI-driven annotation tool hosted on its biomedical research platform.

State Health Officials Alarmed by U.S. Measles Outbreaks, Stress the Importance of Adhering to Established Public Health Practices and Vaccinating the Unvaccinated

Retrieved on: 
Monday, February 26, 2024
Deafness, Measles, Person, Multimedia, Education, Convulsion, Growth, Pneumonia, Vaccination, Risk, Intellectual disability, Sound, Health, Policy, MPH, Knowledge, Brain, Disease, Child, State, Measles vaccine, Public, Vaccine

At least 1 in 5 unvaccinated people in the United States who contract measles is hospitalized.

Key Points: 
  • At least 1 in 5 unvaccinated people in the United States who contract measles is hospitalized.
  • Approximately 1 child out of every 1,000 with measles will suffer brain injury potentially causing convulsions, deafness, or intellectual disability.
  • Thankfully, by following established public health principles, Americans can make informed decisions, prevent outbreaks, and protect our communities.
  • ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in public health practice.

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Retrieved on: 
Thursday, February 22, 2024
Glioblastoma, RAGE, Breast cancer, BIO, Pneumonia, Conference, Patient, Cancer, Pharmaceutical industry

WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.

Key Points: 
  • WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals , Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
  • During the conference, Dr. Marcus will conduct one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
  • Cantex is developing azeliragon, an oral inhibitor of the receptor for advanced glycation end products (known as RAGE).
  • Cantex has ongoing Phase 2 clinical trials in top US and EU medical centers in glioblastoma, brain metastasis, metastatic pancreatic cancer, and breast cancer, and a Phase 3 randomized, placebo-controlled clinical trial in hospitalized patients with pneumonia.

Lung Stent Market to reach $333.8 million, globally, by 2030 at 7.1% CAGR: Coherent Market Insights

Retrieved on: 
Tuesday, February 20, 2024
Boston Scientific, Cook Group, Research, Neoplasm, Traction, Inflammation, Hospital, Quality of life, Stainless steel, Growth, Airway obstruction, Pneumonia, Risk, Chronic obstructive pulmonary disease, Prevalence, Metal, Stent, Patient, Lung cancer, Medtronic, COPD, Uranium mining

The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.

Key Points: 
  • The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.
  • Metal lung stents are expected to dominate the lung stent market in terms of material type.
  • The increasing prevalence of lung diseases, such as lung cancer and pneumonia, is driving the demand for metal lung stents.
  • Tracheobronchial stents and metal lung stents are projected to be the key market opportunities, while North America is expected to dominate the market.

Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, FDA, Medical Devices, Biometrics, Health, Bias, Hospital, Internet, Doctor of Philosophy, Medicine, Multimedia, MD, OTC, Asthma, Oxygen saturation (medicine), Pneumonia, Skin, Confusion, Communication, Pulse, Chronic obstructive pulmonary disease, Safety, Health care, COVID-19, Nursing, Patient, News, Lung cancer, Diagnosis, MASI, COPD, Medical device

Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today FDA clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription.
  • View the full release here: https://www.businesswire.com/news/home/20240213849120/en/
    Joe Kiani, Founder and CEO of Masimo, said, “Until now, consumers and even healthcare providers had no way of knowing what pulse oximeter they could trust to use at home.
  • MightySat Medical provides a direct-to-consumer option for a medical device with hospital-grade pulse oximetry technology, Masimo SET®, whose performance has been reviewed and cleared by the FDA for medical use.
  • Now, MightySat Medical with Masimo SET® provides an FDA-cleared medical device with validated accuracy without the need for a prescription.

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Retrieved on: 
Tuesday, February 13, 2024
Oxygen, International, Chronic kidney disease, Incidence, FDA, Food, Dialysis, Glomerular filtration rate, Pneumonia, Hemofiltration, IRI, Risk, Conference, IMV, Angiopoietin, CRAC, Survivor, COVID-19, Classification, Death, Acute kidney injury, EGFR, AHRF, Patient, Biomarker, AKI, Survival, Disease, Kidney disease, Medicine, GFR, Endothelium, IND, Mortality, Pharmaceutical industry

LA JOLLA, Calif., Feb. 13, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, Auxora™, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.

Key Points: 
  • CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.
  • "Through KOURAGE, we aim to determine how Auxora can benefit patients with severe AKI and potentially reduce the high mortality rate associated with this disease."
  • AKI is classified as stages 1, 2 and 3 depending on the degree of kidney injury.
  • A single dose of Auxora after IRI increased GFR by 61% and decreased mononuclear (inflammatory) cell infiltration by 30%.

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Retrieved on: 
Monday, February 12, 2024
Nitrogen oxide, Conference call, Nitric oxide, Research, PMA, B cell, Hebrew University of Jerusalem, FDA, Clinical research associate, SITC, NOS1, UNO, Pneumonia, Season, ASD, Society, Conference, Commercial, HUJI, Phenotype, Patient, DSM-IV codes, Immunotherapy, VCAP, NTM, Fiscal year, Nontuberculous mycobacteria

“In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.

Key Points: 
  • “In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.
  • This increasing demand for our current LungFit PH system was seen even as we prepared to launch a key software update.
  • As our inventory of upgraded LungFit PH grows, we expect to be able to meet accelerating demand over the next several quarters.
  • General and administrative expenses for the three months ended December 31, 2023 and December 31, 2022 were $9.8 million and $8.9 million, respectively.